Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model
2024; Frontiers Media; Volume: 15; Linguagem: Inglês
10.3389/fphar.2024.1461473
ISSN1663-9812
AutoresBorja Zarate-Tamames, Noé Garín, M Calvín-Lamas, Sonia Jornet, Josefina Martínez‐Simón, Sara García-Gil, Eva M. Garcia-Rebolledo, Ramón Morillo‐Verdugo,
Tópico(s)Asthma and respiratory diseases
ResumoRespiratory diseases encompass a diverse range of conditions that significantly impact global morbidity and mortality. While common diseases like asthma and COPD exhibit moderate symptoms, less prevalent conditions such as pulmonary hypertension and cystic fibrosis profoundly affect quality of life and mortality. The prevalence of these diseases has surged by approximately 40% over the past 3 decades. Despite advancements in pharmacotherapy, challenges in drug administration, adherence, and adverse effects persist. This study aimed to develop and perform an interim validation of a Capacity-Motivation-Opportunity (CMO) model tailored for respiratory outpatients to enhance pharmaceutical care, which is the direct, responsible provision of medication-related care for the purpose of achieving definite outcomes that improve a patient's quality of life, and overall wellbeing.
Referência(s)